Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.

Zentaro SaitoKohei FujitaMisato OkamuraTakanori ItoYuki YamamotoOsamu KanaiMasayuki HashimotoKoichi NakataniSatoru SawaiTadashi Mio

Published in: Cancer reports (Hoboken, N.J.) (2021)

This study suggested that ICIs are an acceptable treatment option for NSCLC patients aged ≥80 years. Oncologists should pay attention to severe irAEs.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
small cell lung cancer
newly diagnosed
prognostic factors
peritoneal dialysis
physical activity
working memory
health insurance
combination therapy